Home › TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)
 

Keywords :   


TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA (pembrolizumab)

2015-05-30 20:00:20| Merck.com - Product News

Dateline City: WALTHAM, Mass., and KENILWORTH, N.J. Clinical Trial Will Evaluate TESAROs PARP Inhibitor with Mercks Anti-PD-1 Therapy in Patients with Breast and Ovarian Cancers WALTHAM, Mass., and KENILWORTH, N.J., May 30, 2015 TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESAROs niraparib plus Mercks anti-PD1 therapy, KEYTRUDA (pembrolizumab), in a Phase 1/2 clinical trial. Language: English read more

Tags: study combination collaborate merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Wind Speed Probabilities Number 7
05.11Tropical Storm Rafael Public Advisory Number 7
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 7
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »